Risk factor control in secondary prevention of cardiovascular disease: Results from the multi-ethnic HELIUS study

Netherlands Heart Journal

Volumn 25, Issue 4, 2017, Pages 250-257

  Minneboo, M ^a   Lachman, S ^a   Snijder, M B ^a   Vehmeijer, J T ^a   Jorstad H T ^a   Peters, R J G ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular disease; Ethnicity; HELIUS study; Risk factors; Secondary prevention

Indexed keywords

ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; DIABETES MELLITUS; DYSLIPIDEMIA; ETHNIC DIFFERENCE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; OBSERVATIONAL STUDY; PHYSICAL INACTIVITY; QUESTIONNAIRE; SECONDARY PREVENTION; SMOKING; SYSTOLIC BLOOD PRESSURE;

EID: 85016486339     PISSN: 15685888     EISSN: 18766250     Source Type: Journal    
DOI: 10.1007/s12471-017-0956-5     Document Type: Article

References (21)

1. Yusuf S. Two decades of progress in preventing vascular disease. Lancet. 2002;360:2–3.
2. Chambless L, Keil U, Dobson A, et al. Population versus clinical view of case fatality from acute coronary heart disease: results from the WHO MONICA Project 1985–1990. Multinational MONItoring of Trends and Determinants in CArdiovascular Disease. Circulation. 1997;96:3849–59.
3. World Health Organization. Reducing risks, promoting healthy life. http://www.who.int/whr/2002/en/whr02_en.pdf?ua=1 [cited 2015. March. 2002;27:9–26.
4. Kerr AJ, Broad J, Wells S, Riddell T, Jackson R. Should the first priority in cardiovascular risk management be those with prior cardiovascular disease? Heart. 2009;95:125–9.
5. Lim SS, Gaziano TA, Gakidou E, et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet. 2007;370:2054–62.
6. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Fifth Jt Task Force Eur Soc Cardiol Other Soc Cardiovasc Dis Prev Clin Pract constituted By Represent Nine Soc By Invit Expert Eur Heart J. 2012;33:1635–701.
7. Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2015; doi:10.1177/2047487315569401.
8. Zaninotto P, Mindell J, Hirani V. Prevalence of cardiovascular risk factors among ethnic groups: results from the Health Surveys for England. Atherosclerosis. 2007;195:e48–57.
9. Bainey KR, Jugdutt BI. Increased burden of coronary artery disease in South-Asians living in North America. Need for an aggressive management algorithm. Atherosclerosis. 2009;204:1–10.
10. Dalton AR, Bottle A, Soljak M, Majeed A, Millett C. Ethnic group differences in cardiovascular risk assessment scores: national cross-sectional study. Ethn Health. 2014;19:367–84.
11. Agyemang C, Bhopal R. Is the blood pressure of people from African origin adults in the UK higher or lower than that in European origin white people? A review of cross-sectional data. J Hum Hypertens. 2003;17(8):523–34.
12. Nederlands: Statline: Regional core numbers The Nederlands http://statline.cbs.nl/Statweb/publication/?DM=SLNL&PA=70072NED& D1=33-50,73&D2=115,126,140,206,212,231,317,407,610,623, 691,693&D3=17-19&HDR=T&STB=G1,G2&VW=T2014 [cited 2015 4 nov].
13. Stronks K, Snijder MB, Peters RJ, et al. Unravelling the impact of ethnicity on health in Europe: the HELIUS study. BMC Public Health. 2013;13:402.
14. Wendel-Vos GC, Schuit AJ, Saris WH, Kromhout D. Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. J Clin Epidemiol. 2003;56:1163–9.
15. Tra J, van der Wulp I, Appelman Y, de Bruijne MC, Wagner C. Adherence to guidelines for the prescription of secondary prevention medication at hospital discharge after acute coronary syndrome: a multicentre study. Neth Heart J. 2015;23:214–21.
16. Gijsberts CM, Seneviratna A, Bank IE, et al. The ethnicity-specific association of biomarkers with the angiographic severity of coronary artery disease. Neth Heart J. 2016;24:188–98.
17. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378:1231–43.
18. Wright JT Jr., Dunn JK, Cutler JA, et al. Outcomes Hypertens Black Nonblack Patients Treat With Chlorthalidone Amlodipine Lisinopril Jama. 2005;293:1595–608.
19. Margolis KL, Dunn K, Simpson LM, et al. Coronary heart disease in moderately hypercholesterolemic, hypertensive black and nonblack patients randomized to pravastatin versus usual care: the anti-hypertensive and lipid lowering to prevent heart attack trial (ALLHAT-LLT). Am Heart J. 2009;158:948–55.
20. Bergmann MM, Byers T, Freedman DS, Mokdad A. Validity of self-reported diagnoses leading to hospitalization: a comparison of self-reports with hospital records in a prospective study of American adults. Am J Epidemiol. 1998;147:969–77.
21. Yamagishi K, Ikeda A, Iso H, Inoue M, Tsugane S. Self-reported stroke and myocardial infarction had adequate sensitivity in a population-based prospective study JPHC (Japan Public Health Center)-based Prospective Study. J Clin Epidemiol. 2009;62:667–73.